作者: Dimitrios Alexopoulos , Anastasia Galati , Ioanna Xanthopoulou , Eleni Mavronasiou , George Kassimis
DOI: 10.1016/J.JACC.2012.03.050
关键词:
摘要: Objectives The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous intervention (PCI). Background Newer P2Y12 inhibitors like and provide stronger inhibition compared clopidogrel. Both agents are efficacious HTPR clopidogrel, but direct comparison between them has not yet been reported. Methods In a prospective, single-center, single-blind study, 44 (of 139 screened, 31.7%) ACS 24 h post-PCI were randomized either 90 mg twice daily or 10 once for 15 days crossover directly alternate treatment another days. was defined as units (PRU) ≥235 assessed by VerifyNow function assay. Results primary endpoint at end 2 periods lower (32.9 PRU, 95% confidence interval [CI]: 18.7 47.2) (101.3 CI: 86.8 115.7) least squares mean difference –68.3 PRU (95% –88.6 –48.1; p Conclusions exhibiting post-PCI, produces significantly higher prasugrel. (Ticagrelor Versus Prasugrel Acute Coronary Syndromes After Percutaneous Intervention; NCT01360437 )